1. ����ҽ�ƴ�ѧ��һ����ҽԺƤ���Բ��ƣ����Ҽ��ص�ѧ�ơ�������“Ƥ����ѧ”�ص�ʵ���ҡ�
2. �Ϸʰ���ҽ�ƴ�ѧ��һ����ҽԺƤ����

��ժҪ�� �׽���-13���ɻ��Th2ϸ��������һ��ϸ�����ӣ�����֢��������������Ҫ���á��о��������׽���-13�����̬������Ӧ��Ƥ�׼��䲻ͬ���ٴ�����������ԡ���Ӧ��Ƥ�׻���Ƥ���а׽���-13ˮƽ�������߲�����Ѫ��IgEˮƽ����������ء��׽���-13�����������ͨ�������ڰ׽���-13Rα1�Ͱ׽���-4R���帴����ʵ�ֵģ�����һ����IL-13Rα2����Ӧ��Ƥ�׵ķ��������������á��о���ʾ������Ӧ��Ƥ���а׽���-13����ͨ�����ٻ����ܰ������ء��׽���-4��˿�۵��׵�����Ƥ����������֢��Ӧ��Ƥ��������Ƥ����ά���������Ϲ���ɥʧ�ȡ����ؼ��ʡ� ��ϸ������13�� Ƥ�ף� ��Ӧ��

FANG Ling, XIAO Feng-li. Institute of Dermatology; Department of Dermatology, First Affiliated Hospital, Anhui Medical University, Hefei 230032, China Corresponding author: XIAO Feng-li, Email: xiaofengli@126.com ��Abstract�� Interleukin-13 ��IL-13��, a cytokine produced by T-helper type 2 ��Th2�� cells, plays a prominent role in the process of inflammation. Many studies have shown that IL-13 gene polymorphism is associated with atopic dermatitis ��AD�� and variation in clinical phenotypes of AD. The level of IL-13 is elevated in skin lesions of AD, which is significantly associated with the increased serum level of immunoglobulin E. The bioactivity of IL-13 is mediated via a complex receptor system consisting of IL-13Rα1 and IL-4R, while the other receptor IL-13Rα2 may inhibit the occurrence of AD. It has been revealed that IL-13 can cause cutaneous allergic inflammation, pruritus, thickening/fibrosis, loss of barrier function in AD via thymic stromal lymphopoietin ��TSLP��, IL-4, filaggrin ��FLG��, and so on. ��Key words�� Interleukin-13; Dermatitis, atopic

������Ȼ��ѧ����